The shortage of the glucagon product GlucaGen HypoKit has been extended by one month after manufacturing delays were expected to last until September 30.
Supplier Novo Nordisk notified the Therapeutic Goods Administration (TGA) about the latest update and in a statement on 28 September, the TGA said that while the current shortage is expected to end by 31 October 2023, this date may change.
In August, the TGA approved several overseas-registered glucagon products due to the critical shortage of GlucaGen HypoKit.
The TGA encourages people to check its medicine shortage reports database for updates about the supply of the product.
Related: TGA advice about GlucaGen HypoKit for patients and healthcare professionals
Send us a message
19 Moore StCanberra ACT 2601AustraliaPhone: (02) 6173 1000
Join ADEABenefits
About Diabetes ConnektCommunity rulesFAQ